Analysts See $-0.26 EPS for Eyegate Pharmaceuticals, Inc. (EYEG)

February 13, 2018 - By reb123z

 Analysts See $ 0.26 EPS for Eyegate Pharmaceuticals, Inc. (EYEG)

Analysts expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report $-0.26 EPS on February, 22.They anticipate $0.12 EPS change or 31.58 % from last quarter’s $-0.38 EPS. After having $-0.24 EPS previously, Eyegate Pharmaceuticals, Inc.’s analysts see 8.33 % EPS growth. The stock decreased 2.81% or $0.02 during the last trading session, reaching $0.67. About 95,601 shares traded. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has declined 40.33% since February 14, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Coverage

Among 2 analysts covering Eyegate Pharmaceuticals (NASDAQ:EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharmaceuticals had 2 analyst reports since November 12, 2015 according to SRatingsIntel. The rating was initiated by Chardan Capital Markets with “Buy” on Wednesday, December 23. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has “Buy” rating given on Thursday, November 12 by Maxim Group.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $11.54 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More notable recent Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: which released: “EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for …” on August 01, 2017, also with their article: “EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract …” published on February 05, 2018, published: “Eyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of …” on December 19, 2017. More interesting news about Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) were released by: and their article: “EyeGate to Present at the 2018 BIO CEO & Investor Conference” published on February 07, 2018 as well as‘s news article titled: “Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.